Cited by 733Nanoparticle-Based Drug DeliveryDrug Transport and Resistance MechanismsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 149 of the 156 references it cites were found in a registry or an index.

Nanomedicine therapeutic approaches to overcome cancer drug resistance

Open access

Markman, Janet L., Rekechenetskiy, Arthur, Holler, Eggehard, Ljubimova, Julia Y.·2013·Advanced Drug Delivery Reviews

DOI 10.1016/j.addr.2013.09.019PMC PMC5812459

Open this paper in CoChat — free account Open PDF

Abstract

Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines that have a high ability for flexible, fast drug design and production based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective. This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance. With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.addr.2013.09.019

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“from normal stem cells versus progenitor cells, is still not clear and may vary from tumor to tumor or by tumor type [48].”
Background
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Prospective identification of tumorigenic breast cancer cells
Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,579 · cited 1×
“Tumor initiating cells were later isolated in breast carcinomas, and it was shown that only a subset of cells could be serially passaged and gave rise to both phenotypically identical and diverse cells consistent with those found in the initial tumor [40].”
Result
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 3×
“Additional stem cell markers including CD44 [38,121] and CD133 [121] have been associated with drug resistance and may serve as potential targets for future nanodrugs to eliminate CSCs and prevent recurrence.”
Background
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 1×
“Inframe deletions in exon 19 and single missense mutations account for approximately 90% of the EGFR mutations, and result in an increased sensitivity to both small molecule inhibitors, gefitinib and erlotinib [52-54].”
Background
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“It is accepted at the current stage of cancer biology that tumors at the same clinical grade and histological status are genetically heterogeneous and contain subclonal populations [33].”
Background
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564 · cited 1×
“Cancer stem cells have also been isolated from medulloblastoma, glioblastoma [41], ependymoma [42], colon cancer [43,44], chronic and acute myeloid leukemia [45], pancreatic cancer [46], and head and neck squamous cell carcinomas [47].”
Background
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197 · cited 1×
“showed that only a very small subset of cells that were CD34+CD38− had the ability to cause AML in NOD/SCID mice, indicating that subpopulations of cells had differential abilities to proliferate and transfer disease [39].”
Background

Flagged first, then by citations

Show all 156 references

7 of the 156 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–600 of 730

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity
Li, H.-F., Xu, Z. Q., Wu, C., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80129 · Cited by 10
“It is worth mentioning that nanomedicine is an emerging form of anticancer therapy based on the assembling of biological molecules into nanosized particles.(34) Previous publications have proven that high leakiness of microvessels and lack of lymphatic drainage give rise to enhanced accumulation and retention of high-…”
Background
Smart micelleplexes
Magalhães, M., Figueiras, A., & Veiga, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813627-0.00007-7 · Cited by 10
Continuous synthesis of drug nanocrystals by solid hollow fiber cooling crystallization
Liu, Q., Zhu, X., Wang, B., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118978 · Cited by 10
Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro
Maleklou, N., Allameh, A., & Kazemi, B. (2016) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-016-0072-7 · Cited by 10
Functionalised nanomaterials for eradication of CSCs, a promising approach for overcoming tumour heterogeneity
Farahmand, L., Darvishi, B., Salehi, M., Kouchaksaraei, S. S., & Majidzadeh‐A, K. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1405426 · Cited by 10
“Perhaps the most important advantage of a properly designed NP is its capability for overcoming MDR characteristic of CSCs mediated by ADP-driven pumps [54].”
Background
Nanotechnology Assisted Chemotherapy for Targeted Cancer Treatment: Recent Advances and Clinical Perspectives
Lan, H., Wú, Z., Zhang, L., Jin, K., & Wang, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200722110808 · Cited by 11
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance
Bessone, F., Dianzani, C., Argenziano, M., Cangemi, L., Spagnolo, R., Maione, F., Giraudo, E., & Cavalli, R. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.65 · Cited by 11
“They can affect pharmacokinetics and biodistribution profiles, favoring the accumulation in tumors either by passive or active targeting and can enhance the intracellular delivery of conventional chemotherapeutics([5,6]).”
Background
Nanotechnology to Combat Multidrug Resistance in Cancer
Akhter, S., Amin, S., Ahmad, J., Khan, S., Anwar, M., Ahmad, M. Z., Rahman, Z., & Ahmad, F. J. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-09801-2_10 · Cited by 10
Clinical and Prognostic Significance of Cell Sensitivity to Chemotherapy Detected In Vitro on Treatment Response and Survival of Leukemia Patients
Kolesnikova, M. A., Васильевна, С. А., Tairova, S., Сергеевич, О. В., Pospelova, T. I., & Аркадьевна, З. М. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9020024 · Cited by 9
Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles
Singh, A., Myklebust, N. N., Furevik, S. M. V., Haugse, R., & Herfindal, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517114450 · Cited by 10
Nanomedicine: next generation modality of breast cancer therapeutics
Thorat, N. D., & Bauer, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820016-2.00001-x · Cited by 10
The Dawning Era of Anticancer Nanomedicines: From First Principles to Application of Silk Nanoparticles
Matthew, S. A. L., & Seib, F. P. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400130 · Cited by 9
Advances in Liposomal Interleukin and Liposomal Interleukin Gene Therapy for Cancer: A Comprehensive Review of Preclinical Studies
Kubbara, E. A., Bolad, A. K., & Malibary, H. M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030383 · Cited by 10
“Some formulations, such as Doxil, have been improved by adding targeting ligands such as monoclonal antibodies (e.g., mAb 2C5) or employing strategies such as hyperthermia in ThermoDox to trigger drug release [116].”
Development of a hybrid paclitaxel-loaded arsenite nanoparticle (HPAN) delivery system for synergistic combined therapy of paclitaxel-resistant cancer
Chen, F.-Y., Zhang, Y., Chen, X., et al. (2017) · Journal of Nanoparticle Research · doi:10.1007/s11051-017-3848-0 · Cited by 9
An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance
Gu, L.-Q., Cui, P., Xing, L., He, Y., Chang, X. Y., Zhou, T., Liu, Y., Li, L., & Jiang, H. (2019) · RSC Advances · doi:10.1039/c9ra01356c · Cited by 9
Advances in nanotechnology-related strategies against melanoma
Pinho, J. O., Lopes, J., Albino, M., Reis, C. P., Matias, M., & Gaspar, M. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85666-9.00009-7 · Cited by 9
Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer
Malla, S., Neupane, R., Boddu, S. H. S., Abou-Dahech, M. S., Pasternak, M. A., Hussein, N. A., Ashby, C. R., Tang, Y., Babu, R. J., & Tiwari, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90951-8.00004-7 · Cited by 10
Therapeutic applications of canine platelets and their derivatives: a narrative review
Bharti, D., Ajith, Y., Sharun, K., et al. (2023) · Topics in companion animal medicine · doi:10.1016/j.tcam.2023.100840 · Cited by 8
Therapeutic Efficacy of Platinum Based Medicines Combined with Various Nanoparticles in the Treatment of Colorectal Cancer: A Comprehensive Review
Meng, X. (2025) · Journal of Cancer Biomoleculars and Therapeutics · doi:10.62382/jcbt.v2i1.32 · Cited by 8
Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives
Zhao, J., Cui, J., Wang, L., et al. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240131 · Cited by 8
The Chemotherapeutic Potential of Gold Nanoparticles Against Human Carcinomas: A Review
Tiloke, C., Phulukdaree, A., & Chuturgoon, A. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47347-7.00028-8 · Cited by 8
Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer
Li, Y., Han, W., He, C., Jiang, X., Fan, Y., & Lin, W. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00362 · Cited by 8
Combined Photothermal/Combination Chemotherapeutic Approach Using Zif-8-Supported Artesunate and Gold Nanorods
Li, X., Wang, J., Li, W., Xu, F., Gao, Y., Cui, T. R., Yang, K., Zhang, W., Ge, F., & Tao, Y. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c01102 · Cited by 8
Advances in nanobubbles for cancer theranostics: Delivery, imaging and therapy
Na, L., & Fan, F. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116341 · Cited by 11
In vitroandin vivoantitumor study of folic acid-conjugated carboxymethyl chitosan and phenylboronic acid–based nanoparticles
Cao, Z., Wang, X., Cheng, X., Wang, J., & Tang, R. (2017) · International Journal of Polymeric Materials · doi:10.1080/00914037.2016.1252346 · Cited by 8
Ibuprofen Release from Poly(ethyl cyanoacrylate) Nanoparticles Prepared by Semicontinuous Heterophase Polymerization
Balleño, J. A., Mendizabal-Ruiz, A. P., Saade, H., et al. (2018) · International Journal of Polymer Science · doi:10.1155/2018/4527203 · Cited by 8
“Among the nanostructures used for drug loading, liposomes, inorganic particles, polymeric micelles, quantum dots, polysaccharide particles, dendrimers, and polymeric particles can be included [5, 6].”
Background
Efficacious Doxorubicin Delivery Using Glutathione‐Responsive Hollow Non‐phospholipid Vesicles Bearing Lipoyl Cholesterols
Kumar, K., Yadav, L., Kondaiah, P., & Chaudhary, S. (2019) · ChemMedChem · doi:10.1002/cmdc.201900335 · Cited by 8
pH-Sensitive Nanomaterials for Smart Release of Drugs
Meher, M. K., & Poluri, K. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817830-0.00002-3 · Cited by 10
Using hierarchical mesoporous Mg–Al LDH as a potential model to precisely load BSA for biological application
Li, X., Liang, L., Tan, Y., et al. (2020) · Journal of Micromechanics and Molecular Physics · doi:10.1142/s2424913020500125 · Cited by 8
Dual-sensitive and highly biocompatible O-carboxymethyl chitosan nanodroplets for prostate tumor ultrasonic imaging and treatment
Meng, D., Guo, L., Shi, D., Sun, X. Y., Shang, M., Xiao, S., Zhou, X., Zhao, Y., Wang, X., & Li, J. (2023) · Cancer Nanotechnology · doi:10.1186/s12645-023-00172-z · Cited by 8
Nanotechnology Applications in Diagnosis and Treatment of Metastasis
Gupta, A. S. (2014) · Nanomedicine · doi:10.2217/nnm.14.94 · Cited by 8
Overcoming of P-glycoprotein-mediated multidrug resistance of tumors in vivo by drug combinations
Saeed, M. E. M., Zeino, M., Kadioglu, O., et al. (2014) · Synergy · doi:10.1016/j.synres.2014.07.002 · Cited by 8
Thermal, spectroscopic and biological studies on solid ibuprofen complexes of heavy trivalent lanthanides and yttrium
Holanda, B. B. D. C., Guerra, R. B., Legendre, A. O., et al. (2016) · Thermochimica Acta · doi:10.1016/j.tca.2016.11.007 · Cited by 8
Selective Targeting of Cancer Cells using Personalized Nanomedicine
Gupta, A., Ahmad, A., Dar, A. I., Bhatt, A., & Khan, R. (2016) · Toxicology and Forensic Medicine - Open Journal · doi:10.17140/tfmoj-1-e005 · Cited by 7
Therapeutic co-assemblies for synergistic NSCLC treatment through dual topoisomerase I and tubulin inhibitors
Xiong, H., Du, C., Ye, J., Zhang, H., Qin, Y., Zeng, F., Song, R., Shi, C., Guo, H., Chen, J., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.054 · Cited by 7
The Effect of Polyhydroxy Fullerene Derivative on Human Myeloid Leukemia K562 Cells
Guo, W., Liu, X., Ye, L., et al. (2022) · Materials · doi:10.3390/ma15041349 · Cited by 7
Ultra‐high‐performance liquid chromatography with tandem mass spectrometry method for cellular toxicity and pharmacokinetic study of PEG1K polymers
Ge, Y., Zhang, N., Zheng, X., et al. (2024) · Journal of Separation Science · doi:10.1002/jssc.202300802 · Cited by 7
Exploring crosslinker effects on fluorescent molecularly imprinted polymers for improved gefitinib delivery in lung cancer theranostics
Dattilo, M., Motta, M. F., Patitucci, F., et al. (2024) · Materials Advances · doi:10.1039/d4ma00391h · Cited by 7
Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
Waghmare, P., Chabukswar, A. R., Raut, K., Gaikwad-Pawar, B., & Jagdale, S. C. (2024) · Exploration of Medicine · doi:10.37349/emed.2024.00236 · Cited by 7
Polyamidoamine dendrimers of the third generation–chlorin e6 nanoconjugates: Nontoxic hybrid polymers with photodynamic activity
Díaz, C. F., Guzmán, L., Jiménez, V. A., & Alderete, J. B. (2021) · Journal of Applied Polymer Science · doi:10.1002/app.51835 · Cited by 7
Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide
Li, M., Jiang, M., Chen, M., et al. (2023) · Nano Research · doi:10.1007/s12274-023-6273-y · Cited by 7
Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome
Henn, J. G., Aguirre, T. A. S., Nugent, M., & Moura, D. J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105254 · Cited by 8
Gas-blasting nanocapsules to accelerate carboplatin lysosome release and nucleus delivery for prostate cancer treatment
Fu, S., Liang, S., Jiang, D., Yang, R., Zhang, Z., Chang, L., Zhang, X., Liu, Y., & Zhang, N. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.05.002 · Cited by 7
Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule
Hu, Q., Wu, W., Wang, M., Shao, S., Jin, P., Chen, Q., Bai, H., Zhao, X., Huang, J., Wang, J., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.020 · Cited by 7
Medicinal Applications of Metal Nanoparticles
Barui, A. K., Kotcherlakota, R., & Patra, C. R. (2017) · doi:10.1002/9783527807093.ch5 · Cited by 7
Two‐pronged reversal of chemotherapy resistance by gold nanorods induced mild photothermal effect
Shang, Q., Chen, Z., Li, J., et al. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10670 · Cited by 6
Light-Responsive Hydrogel with Nano-Microstructures for Bacteria Eradication and Tumor Therapy
Hu, H., Xu, Z., Liu, J., Hu, H., Yang, H., Ma, J., Chen, J., Xu, H., Cai, Z., Wang, X., et al. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c01116 · Cited by 6
Cell membrane-coating nanotechnology: An integrated strategy against the multifactorial pathogenesis of periodontitis
Han, W.-J., He, Z., Xing, J.-W., Zheng, B.-W., Liu, X., Liu, H., Liu, Y., Xiao, Y., & Luo, E. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124139 · Cited by 7
Verification of fasting-mimicking diet to assist monotherapy of human cancer-bearing models
Huang, W., Li, X., Song, H., Yin, Y., & Wang, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115699 · Cited by 6
Phytoconstituent-derived zingerone nanoparticles disrupt the cell adhesion mechanism and suppress cell motility in melanoma B16F10 cells
Chu, L., Chen, J., Chen, Y., Hsieh, S., & Kung, M. (2024) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2024.06.015 · Cited by 6
Combinatorial approach of cannabidiol and active‐targeted‐mediated photodynamic therapy in malignant melanoma treatment
Nkune, N. W., & Abrahamse, H. (2024) · Journal of Biophotonics · doi:10.1002/jbio.202400191 · Cited by 6
Green chemistry: Modern therapies using nanocarriers for treating rare brain cancer metastasis from colon cancer
Khafaga, D. S. R., Muteeb, G., Aswa, D. W., Aatif, M., Farhan, M., & Allam, S. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100213 · Cited by 6
Nanomaterials in Cancer Theranostics
Zhu, L., Yang, L. P. H., & Zhou, Z. (2017) · Nanomedicine and nanotoxicology · doi:10.1007/978-981-10-5864-6_8 · Cited by 6
Self-assembling peptide–etoposide nanofibers for overcoming multidrug resistance
Zhang, L., Yan, L., Gao, S., et al. (2020) · Chemical Communications · doi:10.1039/d0cc06387h · Cited by 6
Non‑coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies (Review)
Drillis, G., Goulielmaki, M., Spandidos, D. A., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12654 · Cited by 6
Synergistic effect of p53 gene/DOX intracellular delivery and P-gp inhibition by pullulan thiomers on cancer cells: in vitro and in vivo evaluations
Priya, S., & Rekha, M. R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb01770a · Cited by 6
Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer
Ranji, P., Heydari, Z., & Alizadeh, A. M. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150706102842 · Cited by 6
Potential of nanoparticles as drug delivery system for cancer treatment
Pelissari, F. M., Neri-Numa, I. A., Molina, G., Ferreira, D., & Pastore, G. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813741-3.00019-4 · Cited by 6
Salubrinal Enhances Doxorubicin Sensitivity in Human Cholangiocarcinoma Cells Through Promoting DNA Damage
Yu, W., Xiang, Y., Luo, G., et al. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2447 · Cited by 6
Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement
Liu, Y., Wang, X., Zhou, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693972 · Cited by 6
“Nanodelivery systems can reduce the exposure of drugs to nontarget sites through targeted delivery, thereby reducing the toxic side effects and multidrug resistance and improving bioavailability (15, 16).”
Background
Current Novel Drug Deliveries for Oral Cancer: A Chronotherapeutic Approach
Sutar, K. P., Shirkoli, N. S., Sutar, P. S., Kurangi, B. K., Dandagi, P. M., & Masareddy, R. S. (2022) · Current Drug Delivery · doi:10.2174/1567201819666220408094520 · Cited by 6
Molecular Self‐Assembly Constructed in Physiological Conditions for Cancer Diagnosis and Therapy
Cong, Y., Qiao, Z., & Wang, H. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800067 · Cited by 6
Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo
Benedetto, G., Fowler, A., Langdon, D., et al. (2025) · Biomolecules · doi:10.3390/biom15081123 · Cited by 5
“NPs can be used for active targeting but also readily accumulate due to the enhanced permeability and retention (EPR) effect because of inconsistencies in vascular pore size associated with tumors [22,23].”
Cyanobacterial scytonemin, a potential photoprotective natural pigment: biomedical, industrial and environmental applications
Behera, A. K., Parida, S., Mandal, A. K., Patra, S., & Jena, M. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04462-5 · Cited by 6
“However, the side effects of these current medications cre - ate a hurdle and tumor cells often develop resistance to these treatments subsequently (Markman et al. 2013).”
Nanovaccines in gastrointestinal cancers
Wang, Y., Huang, P., Li, C., Tu, S., & Yang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680053 · Cited by 5
“Such ﬂ exibility effectively minimizes drug accumulation in non-target tissues, thereby reducing the risk of adverse effects and providing patients with a safer treatment experience (96 – 98).”
Harnessing nanomedicine to target NF-κB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation
BharathwajChetty, B., Aswani, B. S., Shinde, S. S., Alqahtani, M. S., Abbas, M., Sethi, G., Ma, Z., & Kunnumakkara, A. B. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-025-02554-9 · Cited by 7
“Despite considerable advances in the molecular understanding of cancer, the disease continues to outpace existing treat-ment modalities in terms of its complexity and adapt-ability [9].”
Peptide-modified nanoparticles for doxorubicin delivery: Strategies to overcome chemoresistance and perspectives on carbohydrate polymers
Xu, H., Zhang, X., Kang, L., Feng, S., Li, Y., & Zhao, G. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.140143 · Cited by 5
Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition
Kurillová, A., Kvı́tek, L., & Panáček, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060783 · Cited by 5
Transformable self-assembling peptide nanoplatforms with tumor microenvironment responsiveness for tumor stem cell suppression and immunomodulation
Chen, W., Sun, X., Gao, L., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102078 · Cited by 5
“Nonetheless, this medication is restricted by tumor heterogeneity, and early-stage microscopic tumors cannot be enriched by the EPR effect owing to insufficient angiogenesis [23,24].”
HSP90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application
Somu, P., & Paul, S. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_8 · Cited by 5
THE EFFECT OF SOLID LIPID NANOPARTICLES ON TAMOXIFEN-RESISTANT BREAST CANCER CELLS
Eskiler, G. G., Çeçener, G., Dıkmen, G., et al. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2016v8s2.15220 · Cited by 5
Influence of Hydrophobic Chains in Nanocarriers on Antitumor Efficacy of Docetaxel Nanoparticles
Dong, Z., Shen, Y., Zhao, S., Wang, X., Han, M., Zhao, N., Ao, H., & Guo, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01228 · Cited by 5
Nanosponges: In Perspective to Therapeutic Medicine
Shanuja, J., Singh, K., Nandhini, R. S., et al. (2021) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-61021-0_6 · Cited by 5
Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells
Moku, G., Vangala, S., Yakati, V., Gali, C. C., Saha, S., Madamsetty, V. S., & Vyas, A. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210901102425 · Cited by 5
Multifunctional Dendrimers for Drug Nanocarriers
Zhang, T., Zhang, C., Xing, J., Xu, J., Li, C., Wang, P. C., & Liang, X. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-1798-6.ch018 · Cited by 5
Microfluidic-Based Platform for the Evaluation of Nanomaterial-Mediated Drug Delivery: From High-Throughput Screening to Dynamic Monitoring
Yang, Y., Liu, S., & Geng, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190730100051 · Cited by 5
Revisiting principles, practices and scope of technologically relevant 2D materials
Sarmah, H. J., & Mohanta, D. (2021) · Journal of materials research/Pratt's guide to venture capital sources · doi:10.1557/s43578-021-00211-8 · Cited by 5
Mapping Nanomedicine Terminology in the Regulatory Landscape
Pesudo, L. Q., Alexandra, B.-D., Gottardo, S., Rasmussen, K., Wagner, G., Joanny, G., & Bremer‐Hoffmann, S. (2018) · Joint Research Centre (European Commission) · doi:10.2760/404274 · Cited by 5
“Nanodrugs (Markman, 2013) Lipid-based nanoparticles (liposomes)Polymer-conjugate Dendrimers Carbon-based nanoparticles Metallic and magnetic nanoparticles [101]”
Background
Enhanced Antitumor Efficacy and Reduced Myelosuppression by a Supramolecular Complex Composed of Azocalix[4]arene and Sunitinib
Liu, J., Yin, F., Ren, Y., Ming, M., Xie, H., Cai, X., Li, J., Guo, D., & Wang, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02487 · Cited by 4
Multiproperty Polyethylenimine-Caged Platinum Nanoclusters Promote Apoptosis of Osteosarcoma Cells via Regulating the BAX-Bcl-2/Caspase-3/PARP Axis
Wang, J., Zhang, M., Huang, X., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00501 · Cited by 4
Material informatics-driven insights into brain cancer nanocarriers: A bibliometric comparison of PLGA vs. liposomes
Makalew, B. A., & Abrori, S. A. (2024) · OpenNano · doi:10.1016/j.onano.2024.100225 · Cited by 4
Surface engineered AuNPs for paclitaxel-loaded bleomycin delivery as a supplementation therapy
Farooq, M. U., Şahin, Y. M., Naz, M. Y., et al. (2022) · Applied Nanoscience · doi:10.1007/s13204-022-02645-w · Cited by 4
“Overall, BLM-PTX-PEG-AuNPs look promising and alternative mechanisms of DDs known for different therapeutics drugs, overcoming the MDR obstacles and opening new horizons for cancer treatment.”
BackgroundInfluential
The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer
Wilczak, M., Surman, M., & Przybyło, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128326325240723051625 · Cited by 5
PHARMACEUTICAL NANOCRYSTALS: AN EXTENSIVE OVERVIEW
SIVANATHAN, G., RAJAGOPAL, S., MAHADEVASWAMY, G., ANGAMUTHU, G., & Venkatesh, D. N. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i6.52257 · Cited by 4
Research Progress of Hyaluronic Acid-Coated Nanocarriers in Targeted Cancer Therapy
Hou, X., & Zhang, H. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0143 · Cited by 4
Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations
Mandal, M., Banerjee, I., & Mandal, M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01859-z · Cited by 6
BCR/ABL mRNA Targeting Small Interfering RNA Effects on Proliferation and Apoptosis in Chronic Myeloid Leukemia
Zhu, X., Lin, Z., Du, J., Cao, G., & Liu, G. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.12.4773 · Cited by 4
“A single point mutation in the targeted region abolishes mRNA degradation and may cause RNAi-resistance in tumors (Markman et al., 2013).”
Background
Mesenchymal stem cell secretome and nanotechnology: Combining therapeutic strategies
Ferreira, A. L. P., Paris, G. C., de Azevedo, A., Cortez, E. A. C., de Carvalho, S. N., de Carvalho, L., & Thole, A. A. (2022) · Biocell · doi:10.32604/biocell.2022.019363 · Cited by 4
Complexities of Drug Resistance in Cancer: An Overview of Strategies and Mathematical Models
Casadei, B., Giacosa, M., Maula, A., Plos, S., Zappulla, L., Viotto, C., Deriu, M. A., & Tuszyński, J. A. (2022) · Emergence, complexity and computation · doi:10.1007/978-3-031-04379-6_14 · Cited by 4
Effect of different molecular weight and terminal group PLGA on docetaxel nanoparticles: characterization and cytotoxic activity of castration-resistant prostate cancer cells
SIMITCIOGLU, B., Karagöz, I. D., Ilbasmiş-Tamer, S., et al. (2022) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2022.2120004 · Cited by 4
“Recently, to overcome traditional chemotherapy problems and usage anticancer drugs more efficiently in cancer treatment, researchers have focused their attention on the design of delivery systems for anticancer drugs (Markman et al. 2013; Aheget et al. 2020).”
Background
Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents
Barasa, L., Vemana, H. P., Surubhotla, N., et al. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191028101506 · Cited by 4
Nanotechnology and Multidrug Resistance
Nahvi, I., Nahvi, I., Nahvi, I., et al. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_14 · Cited by 4
Polymer Nanoparticles for Cancer Photodynamic Therapy Combined with Nitric Oxide Photorelease and Chemotherapy
Quaglia, F., & Sortino, S. (2016) · Lecture notes in chemistry · doi:10.1007/978-3-319-31671-0_9 · Cited by 4
Research Progress in the Synthesis of Targeting Organelle Carbon Dots and Their Applications in Cancer Diagnosis and Treatment
Fan, J., Li, Q., Chen, L., Du, J., Xue, W., Yu, S., Su, X., & Yang, Y. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3167 · Cited by 4
Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines
Mihaylova, R., Ahmedova, A., Momekova, D. B., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00738-y · Cited by 4
Stromal cell-derived factor-encapsulated nanoparticles target ischemic myocardium and attenuate myocardial injury via proangiogenic effects
Yajima, S., Lee, S. H., Yang, J., Vergel, M. D., Manna, M. K., Kusadokoro, S., Zhu, Y., Elde, S., Mullis, D. M., Venkatesh, A., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123167 · Cited by 3
Berberine-enriched copper oxide nano formulation synthesized using Solanum torvum: A strategic advancement in lung cancer therapy and wound healing
Sakthivel, M. B., Narayanan, P. D. D., Munusamy, T., et al. (2025) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2025.237203 · Cited by 3
“The primary risk factor for causing lung cancer is smoking and it is O n li n e F i r s t with minimal effects on normal cells [9]. of nanoparticles are techniques.”
Research Trends on Nanomaterials and Hepatocellular Carcinoma From 1999 to 2024: A Bibliometric Analysis
Liu, M., Zhong, S.-S., Wang, J., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s516647 · Cited by 3
“16 Specific nanomaterials such as gold nanoparticles, 17 graphene oxide, 18 carbon nanotubes, 19 and polymer nanoparticles 20 have demonstrated significant advantages in tumor treatment.”
Nanomedicines and stroke: Advantages in chronic inflammation treatment and neural regeneration
Liu, C., Ran, Y., Hu, C., Wang, M., Li, N., Yang, Z., Ding, Z., Qiao, C., Xi, J., Su, W., et al. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00120 · Cited by 4
Cancer Cell Detection and Precision Targeting Drug Delivery by Covalently Functionalized Liposome
Ghosh, M., Dasgupta, U., Barman, S., Ray, A., Chatterjee, B. P., Chakraborty, A., Das, U., Chakraborty, P., Pramanik, G., Maity, A. R., et al. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c01225 · Cited by 3

Authors: Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y.
Affiliations: Cedars-Sinai Medical Center (US)
Corresponding author: Ljubimova, Julia Y.
ORCID: Markman, Janet L.
Holler, Eggehard
Ljubimova, Julia Y.
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2013-11
Volume: 65
Issue: 13-14
Pages: 1866-1879
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/j.addr.2013.09.019
PMC: PMC5812459
OpenAlex: W2086374939
Semantic Scholar: 45ee9c859bb1f5d84491499a8da3d69d2e4c8976
Cited by: 733
References: 156
Citations by year: 2026: 23 · 2025: 44 · 2024: 56 · 2023: 50 · 2022: 66 · 2021: 63 · 2020: 68 · 2019: 73 · 2018: 66 · 2017: 67 · 2016: 75 · 2015: 59 · 2014: 22
FWCI: 3.54
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 147 d)
Locations: Advanced Drug Delivery Reviews (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA188743, R01CA123495, R01CA136841, U01CA151815)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: nanomedicine, chemoresistance, drug delivery, multidrug resistance, liposomes, polymer conjugates, micelles, dendrimers, carbon nanoparticles, metal nanoparticles, precision oncology, tumor genomic profiling
MeSH terms: Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Carriers, Humans, Neoplasms, Neoplastic Stem Cells, Drug Design, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Nanomedicine, Nanoparticles, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanomedicine therapeutic approaches to overcome cancer drug resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks